Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, double blinded, placebo controlled study of the effects of 12 weeks DPP-IV inhibitor treatment on secretion and action of the incretin hormones in patients with type 2 diabetes

Next Previous
Trial Profile

Phase 3, double blinded, placebo controlled study of the effects of 12 weeks DPP-IV inhibitor treatment on secretion and action of the incretin hormones in patients with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitagliptin (Primary) ; Dipeptidyl peptidase 4 inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics

Most Recent Events

  • 06 Nov 2012 Investigational drug identified as Sitagliptin as reported by European Clinical Trials Database.
  • 05 Jan 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top